News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
173 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17775)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
2 (104)
3 (173)
4 (173)
5 (128)
6 (1)
7 (23)
8 (258)
9 (151)
10 (98)
11 (90)
12 (52)
13 (1)
14 (1)
15 (70)
16 (158)
17 (130)
18 (132)
19 (69)
20 (4)
21 (3)
22 (130)
23 (153)
24 (124)
25 (141)
26 (79)
27 (1)
28 (1)
29 (133)
30 (155)
31 (147)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Policy
The FDA Fast Tracks 60 Degrees Pharma’s Malaria Drug
The company submitted the NDA in December.
January 4, 2018
·
4 min read
Pharm Country
Envigo Allocates $300M Term Loan B Facility
J.P. Morgan is serving as the administrative agent for the refinancing and joint bookrunners are J.P. Morgan, SunTrust Robinson Humphrey and Barclays.
January 4, 2018
·
7 min read
Zora Announces CERT - A Validated Test for Cardiovascular and Diabetes Risk Prediction
Zora announces the expansion of its Coronary Event Risk Test to include prediction of type II diabetes.
January 4, 2018
·
4 min read
Business
Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
Mr. Wilson joins Crinetics from Cidara Therapeutics, where he was Vice President of Finance and Accounting and Chief Accounting Officer.
January 4, 2018
·
2 min read
Business
Sigilon Therapeutics Appoints David E. Moller, M.D., as CSO
Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.
January 4, 2018
·
3 min read
Business
Predictive Technology Group Appoints Dr. Hugh S. Taylor, M.D. to the Predictive Technology Group’s Scientific Advisory Board
Dr. Taylor’s teaches as Professor of Molecular, Cellular and Developmental Biology at Yale University.
January 4, 2018
·
3 min read
Business
Fabre-Kramer Partners With Mission Pharmacal for Future Commercial Manufacture of Novel Mechanism Antidepressant Travivo (Gepirone Hcl) Tablets
The two companies also expect to enter into an agreement for Mission to manufacture and package the commercial supplies of Travivo once approved.
January 4, 2018
·
5 min read
FDA
Sight Sciences Expands Surgical Portfolio With FDA Clearance of the OMNI Surgical System
In addition to the FDA approval, Sight Sciences also announced three key hires to the leadership team.
January 4, 2018
·
4 min read
Business
Spero Therapeutics Appoints David Melnick, M.D., as Chief Medical Officer
Dr. Melnick to lead clinical team as Spero prepares to enter late-stage clinical trials.
January 4, 2018
·
4 min read
Genetown
Enterome Raises €32M ($38.5M) in a Series D Financing
The proceeds of the fundraising will be used primarily to progress two proof-of concept clinical trials of Enterome’s lead development programs.
January 4, 2018
·
8 min read
Previous
11 of 18
Next